央广网北京11月26日消息 据中央广播电视总台中国之声《新闻和报纸摘要》报道，"十五五"规划 建议提出，推动量子科技、生物制造、氢能和核聚变能、脑机接口、具身智能、第六代移动通信等成为 新的经济增长点。目前我国已形成脑机接口产业链雏形，各地聚焦打通临床应用"最后一公里"，让脑机 接口技术从实验室加速走向产业化应用。 国内首例国产脑机接口脑起搏器植入手术近日在山东济南顺利完成。山东省立第三医院神经外科副 主任张建斌说，国产脑机接口脑起搏器能够实时"读取"患者大脑的信号，实现"按需治疗"。 张建斌：它有两大特点，第一，可以实时采集脑深部的电信号，并且自动调整刺激的参数，患者就 不用频繁到医院去调试设备了；第二，可以明显减少患者手术之后药物的使用量。 今年3月，来自复旦大学附属华山医院的吴劲松团队完成了我国首例侵入式脑机接口临床试验，在 一位四肢瘫痪的受试者大脑运动皮层上方的颅骨内植入了一枚硬币大小的脑机设备，使用的超柔性电极 直径仅为头发丝的百分之一。复旦大学教授、上海脑机接口临床试验与转化重点实验室主任吴劲松介 绍，他们的目标是让患者恢复行动、视听等功能。 黄文鸿：我国在侵入式与非侵入式两大技术路线上均取得重要 ...

Core Insights - The article highlights the significant potential of new materials and flexible electrodes in China, particularly in the field of brain-computer interfaces (BCIs) [1][7] - The approval of the first invasive brain-computer interface product by Shanghai Ladder Medical Technology Co., Ltd. marks a milestone in the domestic medical device industry [1][4] Industry Overview - The innovative medical device special review procedure established by the National Medical Products Administration (NMPA) aims to encourage innovation in medical devices, providing expedited review for products with core technology patents and significant clinical value [2][3] - The invasive brain-computer interface technology requires surgical implantation, which presents higher technical barriers and risks but offers higher quality and precision in neural signal acquisition compared to non-invasive methods [3][4] Company Developments - Shanghai Ladder Medical, founded in 2021, focuses on the development of implantable brain-computer interface technology and has recently completed a 350 million yuan Series B financing round [3][4] - The company's ultra-flexible electrode technology allows for minimally invasive implantation, significantly reducing the risk of tissue damage and immune response [4][6] Clinical Progress - Ladder Medical has initiated clinical trials, with a recent case demonstrating a participant controlling a computer cursor using thought after undergoing the brain-computer interface implantation [6][8] - The company is now the second globally, after Neuralink, to enter the clinical phase of invasive brain-computer interfaces [6][8] Market Potential - The global brain-computer interface market is projected to grow from approximately $2.62 billion in 2024 to $12.4 billion by 2034, with a compound annual growth rate of 17.35% [8] - The Chinese brain-computer interface market is expected to expand from 3.2 billion yuan in 2024 to 6.14 billion yuan by 2028, indicating strong growth potential in the sector [8] Regulatory Environment - Recent policy developments, including the establishment of industry standards for brain-computer interface medical devices, are expected to facilitate faster market entry for approved products [7][8] - The NMPA's new standards for brain-computer interface terminology will take effect on January 1, 2026, marking a significant step in regulatory clarity for the industry [7][8]

Core Viewpoint - Brain-computer interface (BCI) technology has made significant advancements in China, with the inclusion of BCI services in medical insurance and competitive pricing compared to international counterparts like Neuralink [2][3]. Group 1: Technological Advancements - In 2025, China successfully completed its first invasive BCI clinical trial, positioning itself as a key player alongside Neuralink [3]. - The development of ultra-flexible electrodes by companies like JieTi Medical has overcome traditional BCI limitations, allowing for enhanced patient experiences [3][8]. - Neuralink's high-precision invasive technology, while advanced, comes with exorbitant costs, making it less accessible [5][7]. Group 2: Cost and Accessibility - The cost of invasive BCI procedures in China is significantly lower, with prices for invasive surgeries around 6,552 RMB (approximately 912 USD) compared to Neuralink's estimated costs of 5,000 to 10,000 USD [2][3]. - Non-invasive BCI options in China are even more affordable, with prices ranging from 1,000 to 5,000 RMB, making them comparable to mid-range smartphones [15]. Group 3: Competitive Landscape - The competition between Neuralink and Chinese companies highlights differing technological approaches, with the latter focusing on practical, cost-effective solutions [4][8]. - Chinese companies are exploring both invasive and non-invasive technologies, aiming to broaden the application of BCI in various sectors, including healthcare and consumer markets [8][19]. Group 4: Data and Standards Control - The accumulation and analysis of brainwave data are crucial for establishing industry standards, which will determine future market leadership [16]. - Chinese companies are adopting a multi-faceted approach to data collection, enhancing their ability to set standards in the BCI industry [17]. Group 5: AI Integration and Future Prospects - The integration of AI with BCI technology is expected to create a significant data advantage, enabling the development of more sophisticated AI applications tailored to Asian cultural contexts [20]. - China's advancements in BCI technology not only focus on technical superiority but also aim to influence global standards and cultural practices [21].

Group 1 - The "Shenzhen Venture Capital Day" event aims to accelerate the commercialization of technological achievements in the life and health sector, promoting high-quality development of the industry cluster in Shenzhen and the Greater Bay Area [1][3] - The event featured six innovative life and health technology projects, showcasing advancements from basic research to clinical applications [1][2] - Notable projects included a self-adaptive stereotactic radiotherapy system for breast cancer, a flexible electrode for brain-machine interfaces, and a targeted drug for diffuse gastric cancer that has entered phase I clinical trials [2][3] Group 2 - The event facilitated deep exchanges between over 60 investors and representatives from entrepreneurial service institutions, enhancing the atmosphere for investment and collaboration [2] - The integration of innovation resources at the International Headquarters is expected to foster robust growth in Shenzhen's life and health industry [3] - The event serves as a platform for innovative projects to gain visibility and for investment institutions to discover quality projects, thereby injecting new momentum into the cultivation of new productivity and high-quality economic development in the Greater Bay Area [3]

Core Insights - China's invasive brain-machine interface (BMI) technology has entered the clinical trial phase, making it the second country globally to do so after the United States [2][3] - The technology involves a flexible electrode that is 1% the thickness of a human hair, designed to integrate seamlessly with brain tissue [3][4] - The successful implantation and operation of the system mark a significant advancement in the field, with the potential for widespread clinical applications [10][12] Group 1: Technology and Innovation - The electrode developed by the research team is five to seven times smaller in cross-sectional area than those used by Neuralink, showcasing a significant advancement in flexibility and integration with neural tissue [3][4] - The implantation procedure requires only a 5mm puncture in the skull, reducing surgical risks and recovery time compared to traditional methods [3][4] - The system processes neural signals in milliseconds, utilizing an online learning framework to enhance real-time decoding capabilities [3][4] Group 2: Clinical Applications and Future Prospects - The project aims to extend its applications to patients with complete spinal cord injuries, amputations, and conditions like amyotrophic lateral sclerosis, potentially restoring lost functions [12] - The Shanghai Brain-Machine Interface Clinical Trial and Transformation Key Laboratory has been established to facilitate the transition from research to clinical application [4][10] - The system is designed for long-term use, with plans for future upgrades to ensure patients can access the latest technology without frequent replacements [12] Group 3: Collaboration and Research - The collaboration between Fudan University and the Chinese Academy of Sciences exemplifies a synergistic approach to advancing brain-machine interface technology [8][10] - The research team has conducted over 20 simulation implantations prior to the actual procedure, ensuring precision and safety during the operation [8][10] - The system's design includes privacy protection mechanisms to safeguard the neural data collected from patients [11]

Core Viewpoint - The article highlights the significant advancements in brain-computer interface (BCI) technology by the company "阶梯医疗" (Ladder Medical), showcasing its pioneering clinical trials and innovative product designs that position it as a leader in the field within China and globally [1][5][6]. Company Overview - "阶梯医疗" is the first company in China to conduct a prospective clinical trial for invasive brain-computer interfaces, demonstrating its technological leadership in the neural interface sector [5]. - The company has developed the world's smallest brain-controlled implant, measuring 26mm in diameter and less than 6mm in thickness, which is about half the size of similar products from competitors like Neuralink [5]. Clinical Trials and Innovations - The first prospective clinical trial conducted by "阶梯医疗" involved patients with severe motor function impairments, achieving significant results within 2-3 weeks of training, allowing patients to control computers using their thoughts [1][3]. - The trial's success is attributed to the company's rigorous safety and efficacy standards, as well as its collaboration with regulatory bodies to establish testing and evaluation standards for flexible microelectrodes and implanted BCIs [2][4]. Technological Advancements - The company emphasizes the importance of micro-innovation in its products, such as ultra-flexible electrodes that are 1/100th the size of a human hair, which enhance biocompatibility and reduce tissue damage [5][9]. - "阶梯医疗" is also developing a vascular-interventional BCI solution that combines non-invasive surgery with high signal quality, potentially expanding the application of invasive BCIs [5]. Market Potential and Future Goals - The global brain-computer interface market is projected to exceed $25 billion by 2030, with a compound annual growth rate (CAGR) of over 15%, primarily driven by medical applications [7]. - The company aims to enhance its product offerings and expand its market presence by developing various medical devices targeting conditions like depression and epilepsy, while also building a MEMS electrode processing platform to improve production capabilities [6][11]. Collaboration and Industry Position - "阶梯医疗" recognizes the need for collaboration with academic institutions and hospitals to drive innovation and product development, establishing a model that integrates research, industry, and clinical practice [10]. - The company is focused on maintaining its competitive edge by attracting top talent and investing in research and development to strengthen its position in the rapidly evolving BCI market [6][10]. Regulatory Support - The development and registration of invasive BCI products have received strong support from the National Medical Products Administration and various local government initiatives, which aim to foster the growth of the BCI industry in China [4][8].